CGEM vs LEN · $830.3M cap vs rev $34.19B
Cullinan Oncology LLC (CGEM) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Cullinan Oncology LLC (CGEM) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported CGEM revenue for 2022-12-31 was $0. Net income was $109.2M. CGEM currently screens at market cap $830.3M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
CGEM currently screens at market cap $830.3M. LEN currently screens at market cap $0.
Not investment advice. Open the CGEM and LEN stock pages for the full models.
Not investment advice.